Related Experiment Video

Updated: Jun 20, 2026

Creation of Reversible Cholestatic Rat Model
09:39

Creation of Reversible Cholestatic Rat Model

Published on: May 21, 2011

[Genetic cholestasis]

Mirta Ciocca1, Fernando Alvarez

  • 1Hospital Nacional de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina. mciocca@intramed.net

Archivos Argentinos De Pediatria
|September 16, 2009
PubMed

Insights

Molecular genetics advances enable precise diagnosis of progressive familial intrahepatic cholestasis (PFIC) subtypes. Genetic testing and bile acid replacement therapy improve outcomes for children with these rare liver diseases.

Area of Science:

  • Pediatric Hepatology
  • Molecular Genetics
  • Biochemistry

Context:

  • Intrahepatic cholestasis in children presents diagnostic challenges.
  • Advances in molecular genetics have refined understanding of these conditions.
  • Progressive familial intrahepatic cholestasis (PFIC) was previously a broad classification.

Purpose:

  • To highlight the impact of genetic discoveries on diagnosing pediatric intrahepatic cholestasis.
  • To outline the genetic basis of PFIC subtypes (PFIC1, PFIC2, PFIC3).
  • To discuss diagnostic approaches and therapeutic strategies.

Summary:

  • Genetic mutations in ATP8B1, ABCB11, and ABCB4 genes are identified for PFIC1, PFIC2, and PFIC3.
  • Diagnosis relies on clinical, biochemical, and histological data.
  • Inborn errors of bile acid synthesis are a key subset requiring specific management.

Impact:

  • Genetic diagnosis allows for targeted treatment of specific PFIC forms.
  • Therapeutic goals include symptom alleviation and enhanced quality of life.
  • Ursodeoxycholic acid and cholic acid replacement therapy can prevent liver injury progression.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...